Chapter 1
Overview of Financial Reporting, Financial
Statement Analysis, and Valuation
1-19
© 2015 Cengage Learning. All Rights Reserved. May not be scanned, copied or duplicated, or posted to a publicly accessible website,
in whole or in part.
1.13 Value Chain Analysis and Financial Statement Relations. There are various
approaches to this problem. One approach begins with a particular company,
identifies unique financial characteristics (for example, profit margin potential), and
then searches the common-size financial data to identify the company with that
unique characteristic.
Another approach begins with the common-size data, identifies unusual
financial statement relationships (for example, R&D intensity), and then looks over
the list of companies to identify the one most likely to have that unusual financial
statement relationship. This teaching note employs both approaches. All of the data
are scaled by total revenues (except for the final data item, which is cash flow from
operations over capital expenditures); so throughout this discussion when we refer
to a “percentage,” it is a percentage of revenues. The data from Text Exhibit 1.25 in
the text, with company names as column headings, are presented at the end of this
solution in Exhibit 1.E.
Four Firms (1), (3), (4), and (7) incur R&D expenditures, and three do not.
Wyeth, Amgen, Mylan, and Johnson & Johnson engage in research to develop new
products. Thus, they represent these four numbered firms in some combination. One
would expect the firms enjoying patent protection (Wyeth and Amgen) to have the
highest profit margins (that is, net income divided by sales). This would suggest
that Firm (1) is neither Wyeth nor Amgen. Also, Firm (1) has the highest cost of
goods sold percentage of the four companies and its R&D percentage is the lowest,
which are inconsistent with this being Wyeth or Amgen. Products with patent
protection should have the lowest cost of goods sold percentages (resulting from
high markups on cost to arrive at selling prices). Thus, following another line of
logic, the need to continually discover new drugs should lead Wyeth and Amgen to
have the highest R&D percentages, which would be Firm (3) or Firm (4), as
discussed below.
With this being the case, the other two firms—Firm (1) and Firm (7)—are
Mylan and Johnson & Johnson in some combination. The brand recognition of
Johnson & Johnson’s products should give it a high profit margin. Price
competition among generic firms should give Mylan a lower profit margin. This
reasoning would suggest that Johnson & Johnson is Firm (7) and Mylan is Firm (1).
Firm (7) also has higher selling and administrative expenses versus Firm (1),
consistent with Johnson & Johnson. The low profit margin of Mylan is the result of
major ethical drug firms now competing aggressively in the generic market.
This leaves Firms (3) and (4) as Wyeth and Amgen in some order. The
biotechnology industry is significantly less mature than the ethical drug industry.
Few biotechnology drugs have received FDA approval, and research to develop
new drugs is intensive. Given the few biotechnology drugs available in the market,
Amgen’s profit margin as well as its R&D expense percentage should be higher
than those of Wyeth. Thus, Firm (3) is Amgen and Firm (4) is Wyeth. Wyeth’s
higher selling and administrative expense percentage results from its need to
maintain a sales force. The biotechnology products of Amgen are fewer in number
and at this point are essentially pulled through the distribution process by customer
demand. Thus, it has less need for a sales force.